|
Oral Steroid Taper After Total Knee Arthroplasty
NOT_RECRUITINGPhase 1Sponsored by Columbia University
No longer actively recruiting
PhasePhase 1
SponsorColumbia University
Started2025-06-20
Est. completion2026-06-20
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT07070882
Summary
This study aims to evaluate the effectiveness of an oral methylprednisolone taper in reducing postoperative pain, opioid consumption, and nausea following primary total knee arthroplasty (TKA).
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Any patient undergoing primary TKA with a diagnosis of osteoarthritis * \> 18 years old * Willingness to undergo randomization * Patients who will be home by postoperative day (POD) #1 to start the dosing schedule that day (includes both ambulatory and POD #1 discharge patients) Exclusion Criteria: * Reported chronic corticosteroid or opiate use prior to surgery * Prior Open Surgery on the Ipsilateral Knee * Primary diagnosis other than osteoarthritis, including avascular necrosis, fracture, septic arthritis, or postoperative traumatic arthritis * American Society of Anesthesiologists (ASA) score ≥ 4 * Reported history of liver disease, renal disease, or diabetes mellitus * Current systemic fungal infection or other local infection * Immunocompromised or immunosuppressed * Current peptic ulcer disease * History of psychosis, heart failure, myasthenia gravis, ocular herpes simplex virus, or systemic sclerosis * Women with reported current pregnancy * Known hypersensitivity to methylprednisolone * ≤ 18 years old * Inability to take oral medications * Unable to provide consent
Conditions2
ArthritisOsteoarthritis, Knee
Interventions1
Locations1 site
Columbia University Medical Center
Find trials near these locations
Related trials
- A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors — BeOne Medicines
- Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) — Beijing Tongren Hospital
- Effect of Methylprednisolone on Systemic Inflammatory Response During Pediatric Congenital Open-Heart Surgery — Aga Khan University
- Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma — Sun Yat-sen University
- Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia — General Hospital of Shenyang Military Region
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia — National Cancer Institute (NCI)
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) — Merck Sharp & Dohme LLC
- A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients — Oncotherapeutics
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
No longer actively recruiting
PhasePhase 1
SponsorColumbia University
Started2025-06-20
Est. completion2026-06-20
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT07070882